Gland Pharma IPO is all set to hit Dalal street on 09-11-2020. The company aiming for an issue size of ₹ 6,479.55 Crore through this IPO.
Gland Pharma Limited
Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. The company was established in Hyderabad, India in 1978 and has expanded from liquid parenteral to cover other elements of the injectables value chain, including contract development, own development, dossier preparation and filing, technology transfer, and manufacturing across a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. Gland Pharma has seven manufacturing facilities in India, comprising four finished formulations facilities with a total of 22 production lines and three API facilities.
As of March 31, 2020, it had a manufacturing capacity for finished formulations of approximately 755 million units per annum. As of March 31, 2020, the company and its partners had 265 ANDA filings in the United States, of which 204 were approved and 61 were pending approval. The 265 ANDA filings comprise 189 ANDA filings for sterile injectables, 50 for oncology, and 26 for ophthalmics related products.
It manufactures a diversified range of high-quality complex injectables. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc. The company follows a B2B model to sell its products in more than 60 countries including the US, Canada, Australia, India, Europe, etc. Leading pharma companies i.e. Sagent Pharmaceuticals, Apotex Inc. Athnex Pharmaceutical Division, LLC, Fresenius Kabi USA, LLC, etc. are some of the key customers. The company has 7 robust manufacturing units in India comprising 4 finished formulations facilities, 22 production lines, and 3 APIs.
Competitive Strength
- Diversified B2B model with a targeted B2C model in India.
- Robust financial track record.
- Strong manufacturing capabilities.
- Experienced and qualified managerial team.
- The extensive product portfolio of complex injectables.
Objective of the Issue
- To finance the incremental working capital requirements of our Company.
- For funding requirements for capital expenditure requirements.
- General corporate purposes.
Basic details about the company
| Full name | Gland Pharma Limited |
| Sector | Healthcare |
| Industy | Pharmaceuticals-Drugs |
| Company Website | www.glandpharma.com |
Dates to remember
| IPO Open | 09 Novembar 2020 |
| IPO Close | 11 Novembar 2020 |
| Basis of Allotment | 17 Novembar 2020 |
| Refunds date | 18 Novembar 2020 |
| Credit to Demat Account | 19 Novembar 2020 |
| Listing Date | 20 Novembar 2020 |
IPO details
| Issue type | Book Built Issue IPO |
| IPO issue size | ₹ 6,444.68 – ₹ 6,479.55 crore |
| Number of shares offered to the public | 43,196,968 shares |
| Face value | ₹1 per equity share |
| Price band | ₹1490 – ₹1500 per equity share |
| Retail portion | 35% |
| Lot size | 10 Nos |
| Minimum application | 1 lot – 10 shares |
| Maximum application | 13 lot – 130 shares |
| Minimum application amount | ₹15,000 |
| maximum application amount | ₹195,000 |
| Listing Exchange | BSE, NSE |
Category-wise Break up
Anchor: 1,29,59,090 Shares = 1,943.86 Crores
QIB: 86,39,394 Shares = 1,295.91 Crores
NII: 64,79,545 Shares = 971.93 Crores
RII: 1,51,18,939 Shares = 2,267.84 Crores (Lot size:10 = 15,11,894 Forms)
Total Issue: 4,31,96,968 Shares = 6,479.55 Crores.
Financials
| Gland Pharma’s financial performance (in INR crore) | ||||
| FY2018 | FY2019 | FY2020 | Q1 FY2021 | |
| Revenue | 1,671.7 | 2,129.8 | 2,772.4 | 916.3 |
| Expenses | 1,170.2 | 1,423.5 | 1,779.5 | 496.3 |
| Net income | 320.5 | 451.6 | 767.6 | 312.6 |
| Net margin (%) | 19.2 | 21.2 | 27.7 | 34.1 |
Valuation of Gland Pharma (as of FY2020)
| Earnings Per Share (EPS) | ₹49.88 |
| Price/Earnings (PE ratio) | 29.87 – 30.07 |
| Return on Net Worth (RONW) | 21.2% |
| Net Asset Value (NAV) | ₹235.32 per share |
Company Promoters
- Fosun pharma industrial Pte. Ltd.
- Shanghai Fosun Pharmaceutical (Group) Co. Ltd.
Gland Pharma IPO Lead managers
- Citigroup Global Markets India Private Limited.
- Haitong Securities India Private Limited.
- Kotak Mahindra Capital Company Limited.
- Nomura Financial Advisory And Securities (India) Pvt Ltd.
Registrar of Gland Pharma IPO
Link Intime India Private Limited
C-101, 1st Floor, 247 Park Lal Bahadur Shastri Marg, Vikhroli (West)
Mumbai – 400 083
Phone: +91 22 4918 6200
Fax: +91 22 4918 6195
Email: glandpharma.ipo@linkintime.co.in
Website: http://www.linkintime.co.in
Gland pharma Contact Details
Gland Pharma Limited
Sy. No. 143 – 148, 150 and 151,
Near Gandi Maisamma ‘X’ Roads,
D.P. Pally, Dundigal,
Dundigal – Gandi Maisamma (M),
Medchal-Malkajgiri District,
Hyderabad 500 043
Phone: +91 40 3051 0999
Email: investors@glandpharma.com
Website: www.glandpharma.com
Gland pharma IPO allotment Status
Gland Pharma IPO allotment status will be available on Link Intime’s website.
Click on this link to get allotment status.
Final thoughts
Gland Pharma IPO is going to hit Dalal street soon. applying for IPO is purely a personal choice. study well about the company and do subscribe if you are feeling good about the company. I hope this post gave you enough details to make a fundamental study of the company. learn well and make a wise decision
Happy Investing
Pingback: IPO List, current-ongoing-listed IPOs - finvestfox.com